DJ Precisis AG: second round of funding secured and entry in the epilepsy therapy market
(DGAP-Media / 03.04.2014 / 18:20)
Precisis AG secures second round of financing and enters the epilepsy therapy market
Heidelberg, 3rd April 2014. Precisis AG has secured a new strategic investor. The new partner is closely involved with the successful German pharmaceutical manufacturer URSAPHARM and through the partnership with Precisis AG aims to support the development of further innovative therapy solutions. STRIVE AG, an established shareholder of Precisis AG will also continue to invest in the company.
"We were very impressed with the development of a completely novel method of brain stimulation and also the dynamism and experience of the company management. These are prerequisites for the success of modern technologies in the current health market", so Dominik Holzer, General Manager of URSAPHARM Arzneimittel GmbH and U.B.H. Innovation GmbH, speaking on behalf of the new investor.
Precisis AG develops high precision medical technology instruments for the treatment of major brain disorders. The product portfolio includes planning software and hardware products in the area of neurosurgery, add-on-collimators and robots for brachytherapy in the area of neuroradiology. Additionally a new minimally invasive brain stimulation system is in the development pipeline since 2013. Overall the company has achieved considerable growth following the entry of STRIVE AG as shareholder in 2011.
Precisis AG plans on investing in the further development of the new electrode system in order to prepare it for market entry. The innovative, minimally invasive system, which is patented worldwide may improve the treatment prospects for patients with refractory epilepsy and enable a higher quality of life. Precisis AG, together with its new investor, has defined several milestone-based rounds of funding, to ensure successful completion of the complex registration process in place for intelligent, implantable electrode systems. As Precisis AG holds worldwide patent rights not only for the unique electrode system, but also the anatomical space, it is possible that a successful conclusion of the current project will result in the exploration of further therapeutics areas.
The new investor is assigned a seat on the Precisis AG supervisory board and this position will be occupied by Julia Mopin, Diplom Betriebswirtin and copartner of URSAPHARM Arzneimittel GmbH.
About Precisis AG
Precisis AG sees itself as an innovative solution provider for the treatment of major brain disorders. In addition to the enhancement of established precision software systems, such as PraezisPlus(R) and Virtuos(R) and the development of multi-leaf collimators, as well as robots for brachytherapy, the Heidelberg-based medical technology provider is now working to develop a new treatment modality for epilepsy using brain stimulation. In order to achieve this Precisis AG is cooperating with world renowned epileptologists and the Biomedical Institute of MIT, Cambridge. Precisis AG maintains a subsidiary in Boston. The German team is led by company president Dr. Angela Liedler, the Boston Team by the physicist and experienced company founder Dr. -Ing. Wolfgang Daum.
Read the original here:
DJ Precisis AG: second round of funding secured and entry in the epilepsy therapy market